News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NST NeuroSurvival Technologies Ltd. Release: APOSENSE(R) [18F]-ML-10 for Molecular Imaging of Apoptosis to Proceed to Phase I/II Trials



7/23/2008 10:44:28 AM

PETCH-TIKVA, ISRAEL--(Marketwire - July 23, 2008) - NST NeuroSurvival Technologies Ltd. (NST), a clinical phase company developing molecular imaging agents and drugs that identify and target cells undergoing apoptosis (programmed cell death), today announced that the U.S. Food and Drug Administration (FDA) issued a "safe to proceed" letter for the company's APOSENSE® [18F]-ML-10 Investigational New Drug Application (IND).

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES